By Nitesh Bhele
Japan is the 2nd largest Pharmaceutical & biotechnology market in the world after the United States. Japan accounts for around 10 percent of the global pharma market, compared with 39 percent for the U.S. and 21 percent for Western Europe approximately. The pharmaceutical market has size around $ 150 billion, where biotechnology market value of Japan is projected to sharply increase reaching $100 billion by 2020. The Japan government recognized the big demand on this sector and realized the need of having a national strategy for Pharmaceutical & biotechnology development. Number of plans based on the Biotechnology Strategy Guidelines have been implemented since last few years.
Currently, Japan still lags behind the U.S. in this sector but it is taking a lead in the field of gene analysis, genetic recombination, bioinformatics and others. With the great effort of the government by providing substantial resources to this sector, biotechnology is expected to become a major sector. Furthermore, The Industrial Cluster Plan Policy is one of the efforts of the government to strengthen the capabilities of the defined regional cluster areas to develop new technologies and product. Among the 17 projects, 8 of them are focused on the biotechnology industries. Moreover, Japan has a much lower penetration of generics compared to most of the major markets which is advantageous for the big pharma.
In Japan, every citizen has to participate in the insurance program managed by Government of Japan National Health Insurance (NHI). National Health Insurance (NHI) scheme as well as the majority of health care spending is publically funded. The government is taking number of initiatives to control spending, such as encouraging use of cheaper generic drugs, self-management of chronic diseases, and preventive care. A biennial NHI pricing review usually results in price reductions. This also is one of the most significant challenges faced by pharmaceutical companies in the Japanese market is the practice of biennial price cuts. Overall, the average cut of 5.64% will be applied on a drug price basis in the 2014 price revisions similar to the price cut of 6% applied in the 2012 price revisions. Market expansion based re-pricing rules as well as the special additional price cut being implemented this year on products for which the first generic was approved five years ago and have less than 20% generic replacement rate by volume will hamper the growth of the domestic pharmaceutical industry In addition, a new health technology assessment (HTA), expected to be implemented in 2016, could make it more difficult for life sciences companies to obtain competitive launch pricing and market access unless the new treatment is deemed innovative and cost-effective. Also, while the use of cost-saving generic drugs has been proportionally lower in Japan than in other developed markets, the government has strengthened the incentives for healthcare providers to prescribe generics. The new drug development premium awarded to innovative products shields the products from biennial National Health Insurance (NHI) price reductions during their patent protection period. This premium will enable patented branded products in its market expansion. During the 2014 NHI price revisions, 397 active ingredients (758 products) have been granted the exemption, over and above the 367 active ingredients considered for the treatment in the 2012 revision.
(All statements made in this video/article does not reflect our personal interest or belief about pharmaceuticals here at Nihon Scope)
Takeda Pharmaceutical, Japan’s largest pharmaceutical company and Asia and a top 15 pharmaceutical company. The company has over 30,000 employees worldwide, looks likely to increase its global footprint merger & acquisition done by it all over world. Otsuka’s $3.5bn acquisition of California-based neurologic disease specialist Avanir Pharmaceuticals in December 2014 is an even more potent demonstration of Japanese companies’ greater focus on global M&A.
Indeed, generic manufacturers from around the world – but especially generic specialists such as India – are looking to Japan as a source of future expansion. According to the Economic Times, Indian generics giants including Dr Reddy’s, Lupin, Sun Pharma and Glenmark are exploring options for tapping into the growing Japanese generics market.
Active pharmaceutical ingredient (API) and generic finished dose suppliers who recognize this growth potential and understand the specific needs and challenges unique to the Japanese market stand to see significant earnings in this region over the coming years. The global Active Pharmaceutical Ingredient Market is expected to reach USD 205.51 billion by 2020 from USD 150 billion in 2015, at a CAGR of 6.5% during the forecast period .The active pharmaceutical ingredient (API) market in Asia is growing at an increasingly rapid pace. From 2007 to 2011, it went from 24.5 to 28.5 percent of the world market. From now through 2017, it should expand at a rate of 8.2 percent annually. This puts Asia’s API market worth $33 billion currently at more than $50 billion by 2017.
Japan has long led the rest of Asia in demand for APIs. In 2012, the market for APIs in Japan was the largest in Asia, at $15.5 billion. Many foreign API firms from India, Europe and the US are actively selling their APIs on the Japanese market. Japan’s share of innovator APIs is high, and demand is growing especially in the biotech drug sector. But API generics are also starting to gain ground in Japan. Chinese and Indian firms have recently flooded Japan’s market with inexpensive APIs. The accompanying price competition has forced some Japanese API manufacturers out of their own domestic market. An increasing number of foreign pharmaceutical companies are selling APIs on the Japanese market. Sometimes they sell to domestic drug manufacturers and sometimes they sell to foreign drug companies manufacturing products in Japan.
In April 2013, India’s Dishman Pharmaceuticals and Chemicals announced the company was on track to post an almost fivefold growth in revenue for APIs sold in Japan through the end of 2013. Revenue from Japanese sales reached $2 million in 2012, and 2013 revenue is expected to increase to $10 million. The company currently supplies APIs to more than 10 Japanese companies. In February 2012, Pfizer Japan launched two new APIs in Japan. One was part of the diabetes treatment glimepiride (Amaryl), while another was part of the antiarrhythmic agent pilsicainide (Sunrythum). Aside from these two APIs, Pfizer Japan launched another 16 APIs in Japan in 2012. If foreign API manufacturers pay attention to the Japanese API market, they will find excellent sales opportunities, especially in the innovative and generic API segments. Key market players Teva Pharmaceuticals limited (Israel), Sun Pharmaceuticals Industries Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Aurobindo (India), Novartis International AG (Switzerland), Boehringer Ingelheim (Germany), Albemarle Corporation (U.S.), Sigma Aldrich (U.S.), Mylan (U.K.), Allergan plc. (Ireland). Stakeholders include Manufacturers of API Distributors and Suppliers of APIs, Potential Investors in the API Market, Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations and Healthcare Payers
According to Catenion’s , pharmaceutical industry of Japan faces two fundamental problems for which it has not yet found an answer; these problems are firstly, an inadequate approach to managing innovation and secondly, a profound misunderstanding of the nature of risk and consequently poor risk management. The industry’s poor innovation track record is shown by the statistics of drug approvals by the FDA. There has been a long-term trend of a decrease in the number of NCEs and NBEs despite rapidly increasing R&D budgets. A recent study by Czerepak and Ryser published in Nature Drug Discovery shows that for the period between January 2006 and December 2007, barely 35% of the drugs approved by the FDA originated in the pharmaceutical industry. Less than half of these qualified for the label “novel drug and new chemical structure”.
Industry critics have used statistics such as these to argue that Big Pharma is shying away from true innovation and pursuing mostly me-too projects. A quick look at company pipelines shows this to be a wrong conclusion. There is an abundance of exciting, highly innovative projects and risky science going on at most companies. While some industry observers and investors continue to hope there might be an innovation backlog in the wake of unprecedented progress in molecular biology, disease understanding, lab technologies and novel drug formats, others are more pessimistic.
Turning to the second issue, Catenion have identified, the pharmaceutical business is a risky business par excellence but the nature of risk is often not fully appreciated by operators. Of course pharmaceutical executives know the scientific, technical, regulatory and commercial risks of their business. They spend a lot of their time devising and executing risk mitigation activities for these risks at the operational level. The argument we wish to make here is that there is too little awareness that risk must be managed properly at the strategic level as well. Such strategic risk management requires more sophisticated methods than those generally used in the industry today. There are three major points to our argument, covering the nature of risk itself, correlated risk in the R&D pipeline and the degree of risk diversification at the corporate level.
(All statements made in this video/article does not reflect our personal interest or belief about pharmaceuticals here at Nihon Scope)
Lupin is the only Indian pharma company to have a presence in the Japanese generic market from which it currently earns about 12% of annual revenue. Till date, Lupin Ltd has made two buyouts in Japan: Tokyo-based I’rom Pharmaceutical Co. Ltd in 2011 and Kyowa Pharmaceutical Industry Co. Ltd in 2007. Sun Pharma, which acquired Ranbaxy Ltd for $4 billion last year, also plans to raise up to Rs.12,000 crore through convertible debentures or a qualified institutional placement (QIP) for expansion and acquisitions. Japan, where drug sales were estimated at $115 billion in 2013, accounts for nearly 10% of the global pharma market according to a 2014 Deloitte report. The growth will mainly come from higher generic penetration. The government is keen to have a larger generic share to reduce their healthcare costs. An ageing population and mounting health costs have prompted the Japanese government to try and increase the presence of generic drug makers, bringing the Japanese market under the radar of Indian pharmaceutical companies.
According to Deloitte report, Japan’s rapidly ageing population just over a quarter of the population was aged 65+ in 2013, up from 12% in 1990, and accounting for over 50% of the country’s healthcare costs is expected to drive demand for pharmaceuticals in 2014-2018.The state-funded National Health Insurance scheme covers every citizen in Japan. In 2010, as part of efforts to increase the generic penetration, the government launched a series of reforms targeting 30% of the drug market by 2014 and 60% by 2017, from 18% in 2010.
Besides the reported move by Sun Pharma, other Indian generics makers, including Dr Reddy’s Laboratories and Glenmark Pharmaceuticals Ltd, are exploring options for entering Japanese generics market with their formulation drugs.
By Nitesh Bhele, Pharmaceutical & Healthcare Marketer
Full article here – Page No 60
Review of Oct 2017
This page has been made to write a review of my wife and I’s experience about living at Sharely Style Verde shared housing in Fukuoka. Right now they will be receiving a 1 star (See update below) because they currently are deciding to steal our deposit because they made a mistake thinking we wanted to move out later then we did, despite us telling them in writing that we wanted to move out on the 4th.
If they still decide to keep the money and steal from us I will be writing a fair review either way, but it will be noted that they will not be honorable when it comes down to money and how they treat that side of the business. I would also recommend never speaking with the staff about anything related to the money side of the business because they’re easily confused.
We managed to get about $400 back of our deposit (a month or so after the first review), still upset that we had to even negotiate that honestly when we never said anything about STAYING. A lot of these places have trouble understand English so keep things to yourself, if you’re going to move out, MOVE OUT and don’t say ANYTHING otherwise until you KNOW you need to tell them you need to stay.
Overall, I can’t say that I dislike Verde completely, I actually have very fond memories of living their and would consider it again, so $100 out. Whatever I’m over it for the most part. Just take the lesson we learned to heart before moving to Japan, you can stick your foot in your mouth because they have trouble with English. I would actually and have recommended Verde a bit since this post, so even though they pissed us off something fierce in the moment overall it’s a good place, Sharely Style Hakata was pretty gross a lot of the time and the upper kitchen stunk pretty bad. But overall if you stay in the lower kitchen I think from what I saw was a decent place to stay while going to school or working for awhile.
Star wise I’d give them a 4 stars overall besides adding in the confusion part, if I was to add that back in I’m thinking more 2.5 but the staff is always changing so there is never the same person really handling that part and it’s easy to say not all of them would have done that.
Before I came to Japan, I was going through the options of where I was going to live at. In the end I ended up going with a place called Sharely Style Verde. Although it’s a decent place to first come to when arriving in Japan, it certainly has sort of a high price tag to live here. Then they tack on fees to use their beds and to park your bike etc. They rent their beds out for around $30 a month, so I decided that it would be best that I purchased a futon instead of renting a bed. But the big thing about this was that I lived in Colorado, USA at that time. So it was tough to decide how I was going to go about buying one, full well knowing I wouldn’t be able to touch or feel the futon before purchasing it. It felt like it was almost like gambling.
But the big thing that I was worried about was it being big enough yet not breaking the bank and then being able to have it shipped to SSV in time before we got to Japan. Otherwise, my wife and I would have to sleep on the floor, and after a super long flight that is one thing, I was not interested in doing. I was searching all over the place from Amazon, to Wayfair and trying to figure out the best futon to purchase. The thing about all this was that even if the futon was somewhat affordable and big enough the shipping blew it out of the water. Then I stumbled upon a company called “Futon Beds from Japan, ” and they had authentic Japanese futons for sale. The great thing about running into them was that they’re FROM Japan and they were only a prefecture away from Fukuoka, so it was super simple to ship, and it arrived before we got here.
It was a super awesome find, and it was quite affordable. Being that I’ll be here in Japan for over 2 years and in the end moving to another place after my stay at SSV I figured I’ll save the $30/m and get a bed that I can take with me. The other cool part about running into this company is that they also sell kakebuton quilts. Being able to purchase a quilt set certainly was convenient. Here is a picture of the futon set we ended up going with, I’d take a picture of ours (and have, which can be seen on our FB page but it’s covered with sheets, and we have a mesh covering for the kakebuton, so it’s a bit hard to see it.
I highly recommend checking them out if you’re looking to buy a Japanese futon and if you need help ask for Dean he can help you figure out what you need, just like he did for my wife and me.
So far as a review of the bed:
I got a queen sized and for the most part as long as I stretch the bed back out before going to sleep it is more than long enough for me (I’m 6 foot 2 inches) and big enough for a couple. The thickness is way better than I was expecting honestly, although at times I do notice the floor after a while of lying on my side and my hip digging in the bed. Other than that, no complaints at all, and Dean also stated to me that many people use a cushion set under the bed. My wife and I have not felt it necessary to do that, and our room is a fake hardwood with concrete underneath, so it works pretty well.